drugset / Trial / NCT01906164

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

NCT01906164

Phase 1 Completed 101 enrolled Alios Biopharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) of orally administered ALS-008176 in healthy volunteers.

Timeline

Start
2013-05-31
Primary completion
2013-11-30
Completion
2013-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumicitabine Small molecule Oral